Soffinova Partners

Noema Pharma is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address the most disabling symptoms associated with conditions such as Tuberculosis Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By prioritizing patient needs, Noema Pharma seeks to create effective treatments that significantly improve the quality of life for individuals suffering from these challenging conditions.

Polyneuron Pharmaceuticals AG is focused on developing innovative therapeutics for the treatment of antibody-mediated autoimmune disorders. The company is working on several drug candidates, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron utilizes a platform technology called Antibody-Catch, which is based on biodegradable glycopolymers. This technology selectively targets and eliminates pathological autoantibodies while preserving the integrity of the rest of the immune system. Founded in 2014 and headquartered in Basel, Switzerland, Polyneuron aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system.

Polyneuron Pharmaceuticals AG is focused on developing innovative therapeutics for the treatment of antibody-mediated autoimmune disorders. The company is working on several drug candidates, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron utilizes a platform technology called Antibody-Catch, which is based on biodegradable glycopolymers. This technology selectively targets and eliminates pathological autoantibodies while preserving the integrity of the rest of the immune system. Founded in 2014 and headquartered in Basel, Switzerland, Polyneuron aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system.

MD Start SA offers fund placement services to medical device start-up corporations. It has partnerships with Medtronic, Sofinnova Partners, Sorin Group, Versant Ventures, Contract Medical International, and Corscience GmbH & Co. KG. The company, formerly known as Medical Device Accelerator, was founded in 2009 and is based in Lausanne, Switzerland.

ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, focused on developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012, ObsEva aims to address significant medical needs in this area, particularly through its lead product, Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist intended to treat pain associated with endometriosis and heavy menstrual bleeding linked to uterine fibroids in pre-menopausal women. The company is also advancing OBE022, a selective oral prostaglandin F2α receptor antagonist for treating preterm labor in women between 24 to 34 weeks of gestation, and Nolasiban, an oral oxytocin receptor antagonist designed to improve clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The founding team comprises experienced professionals in reproductive medicine and biopharmaceuticals, bringing a wealth of expertise to the company's mission.

Asceneuron SA is a biotechnology company based in Lausanne, Switzerland, founded in 2012. It specializes in the discovery and development of therapeutics for neurodegenerative disorders, particularly focusing on conditions with significant unmet medical needs, such as progressive supranuclear palsy, orphan tauopathies, Alzheimer's disease, and Parkinson's disease. Asceneuron aims to address the challenges posed by tauopathies, which are currently untreatable and characterized by the accumulation of tau protein deposits in the brain, leading to severe neurodegeneration. The company seeks to develop small molecule drugs that can provide effective treatment options, as existing therapies for Alzheimer's disease and related conditions offer limited benefits. With an increasing aging population, the burden of neurodegenerative diseases is expected to grow, highlighting the urgent demand for innovative and better-tolerated therapeutic solutions. Asceneuron operates as a subsidiary of Merck KGaA, reinforcing its commitment to advancing treatments in this critical area of healthcare.

They at Auris Medical are dedicated to developing novel pharmaceutical therapies to protect hearing, silence tinnitus and restore balance. Auris Medical is the leading pioneer in the emerging field of therapies for neurotologic disorders affecting the inner ear. They have two projects in advanced clinical development, Keyzilen® for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. In addition, they have AM-125 in early clinical development for the treatment of vertigo. They have additional projects under development and are further strengthening their pipeline through collaborations with leading academic institutions in this field.

GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections. The company was incorporated in 2004 and is based in Schlieren, Switzerland. As of February 11, 2015, GlycoVaxyn AG operates as a subsidiary of GlaxoSmithKline plc.

PregLem is a Swiss based specialty biopharmaceutical company dedicated to the development and commercialisation of innovative drugs for women's reproductive medicine.

GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections. The company was incorporated in 2004 and is based in Schlieren, Switzerland. As of February 11, 2015, GlycoVaxyn AG operates as a subsidiary of GlaxoSmithKline plc.

PregLem is a Swiss based specialty biopharmaceutical company dedicated to the development and commercialisation of innovative drugs for women's reproductive medicine.

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to the discovery and development of innovative small-molecule pharmaceutical products aimed at treating central nervous system (CNS) disorders. The company specializes in creating oral allosteric modulators that target G-protein coupled receptors, which are crucial for therapeutic interventions. Its leading programs include Dipraglurant, designed for treating levodopa-induced dyskinesia and dystonia in Parkinson’s disease, ADX71149 for epilepsy and other undisclosed CNS disorders, and a GABAB PAM aimed at addressing addiction. Addex Therapeutics has established a collaboration with Janssen Pharmaceuticals to advance the development of mGluR2PAM compounds for human health applications. Founded in 2002, the company has evolved its focus and pipeline based on a pioneering drug discovery platform that emphasizes allosteric modulation.

GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections. The company was incorporated in 2004 and is based in Schlieren, Switzerland. As of February 11, 2015, GlycoVaxyn AG operates as a subsidiary of GlaxoSmithKline plc.

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to the discovery and development of innovative small-molecule pharmaceutical products aimed at treating central nervous system (CNS) disorders. The company specializes in creating oral allosteric modulators that target G-protein coupled receptors, which are crucial for therapeutic interventions. Its leading programs include Dipraglurant, designed for treating levodopa-induced dyskinesia and dystonia in Parkinson’s disease, ADX71149 for epilepsy and other undisclosed CNS disorders, and a GABAB PAM aimed at addressing addiction. Addex Therapeutics has established a collaboration with Janssen Pharmaceuticals to advance the development of mGluR2PAM compounds for human health applications. Founded in 2002, the company has evolved its focus and pipeline based on a pioneering drug discovery platform that emphasizes allosteric modulation.

Esmertec is one of the leading independent software companies focusing on Java™ solutions and technologies for mass-market devices such as mobile multimedia phones, personal digital assistants and home multimedia systems. Their Java device platforms enable major terminal manufacturers, operators and content providers worldwide to deliver wide ranges of customised multimedia services to large groups of consumer audiences.

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to the discovery and development of innovative small-molecule pharmaceutical products aimed at treating central nervous system (CNS) disorders. The company specializes in creating oral allosteric modulators that target G-protein coupled receptors, which are crucial for therapeutic interventions. Its leading programs include Dipraglurant, designed for treating levodopa-induced dyskinesia and dystonia in Parkinson’s disease, ADX71149 for epilepsy and other undisclosed CNS disorders, and a GABAB PAM aimed at addressing addiction. Addex Therapeutics has established a collaboration with Janssen Pharmaceuticals to advance the development of mGluR2PAM compounds for human health applications. Founded in 2002, the company has evolved its focus and pipeline based on a pioneering drug discovery platform that emphasizes allosteric modulation.

Esmertec is one of the leading independent software companies focusing on Java™ solutions and technologies for mass-market devices such as mobile multimedia phones, personal digital assistants and home multimedia systems. Their Java device platforms enable major terminal manufacturers, operators and content providers worldwide to deliver wide ranges of customised multimedia services to large groups of consumer audiences.